



# MARKET RELEASE

7 March 2018

## **Immuron Limited**

### **TRADING HALT**

The securities of Immuron Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Friday, 9 March 2018 or when the announcement is released to the market.

Security Code: IMC

Kate Kidson

**PRINCIPAL ADVISER, LISTINGS COMPLIANCE (MELBOURNE)**

Wednesday 7<sup>th</sup> March 2018

Kat Kidson  
Principal Adviser Listings Compliance (Melbourne)  
ASX Compliance Pty Ltd  
Level 4, North Tower Rialto,  
525 Collins Street, Melbourne, VIC. 3000

Sent via email: [kate.kidson@asx.com.au](mailto:kate.kidson@asx.com.au) and [tradinghaltsmelbourne@asx.com.au](mailto:tradinghaltsmelbourne@asx.com.au) .

Dear Kate;

**RE: Request for Trading Halt**

In accordance with ASX Listing Rule 17.1, the Directors of Immuron Limited (the Company) requests an immediate trading halt in respect of its securities, ASX Codes, IMC, and IMCO.

In requesting the trading halt the Company provides the following information:

- The trading halt is necessary as the Company finalises its announcement to the market in respect to the release of its Phase II NASH Clinical Trial Results;
- Unless otherwise requested by the Company, the Company requests the trading halt to remain in place until the announcement is made to the market which is anticipated to be on Thursday 8<sup>th</sup> March 2018;
- The Company is not aware of any reason why the trading halt should not be granted or of any information necessary to inform the market about the trading halt.

For and on behalf of the Company,

Kind Regards;



Peter Vaughan  
Company Secretary  
Immuron Limited